Featured Research

from universities, journals, and other organizations

Leptin resistance may prevent severe lung disease in patients with diabetes

Date:
February 12, 2011
Source:
American Thoracic Society
Summary:
Resistance to leptin, a protein that plays a key role in regulating metabolism and appetite, may help prevent the development of acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) in individuals with type II diabetes, according to a study conducted by researchers in Chicago. The study indicates leptin resistance, a common characteristic of diabetes, may help prevent the formation of inflexible, fibrous tissue that develops in ALI and ARDS.

Resistance to leptin, a protein that plays a key role in regulating metabolism and appetite, may help prevent the development of acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) in individuals with type II diabetes, according to a study conducted by researchers in Chicago. The study indicates leptin resistance, a common characteristic of diabetes, may help prevent the formation of inflexible, fibrous tissue that develops in ALI and ARDS.

The findings were published online ahead of the print edition of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

"Previously it was hypothesized that hyperglycemia, the hallmark of diabetes might be responsible for the lower level of ARDS seen in these patients," said study author Gφkhan M. Mutlu, MD, associate professor, Division of Pulmonary and Critical Care Medicine, Northwestern University Feinberg School of Medicine. "However, subsequent studies have indicated hyperglycemia exacerbates inflammation and worsens lung injury. Our findings provide support for the hypothesis that leptin resistance plays a key role in offering protection against ARDS in diabetic subjects."

ALI and ARDS are common clinical conditions affecting almost 200,000 people per year in the United States, with mortality rates of about 40 percent. Severe infection, or sepsis, is the most common cause of ALI/ARDS. There are no therapies directly targeting ALI and ARDS and the treatment remains largely supportive, including the use of mechanical ventilation. Some patients with ARDS develop lung scarring, which is associated with worse prognosis.

Previous studies have shown patients with diabetes have about a 50 percent lower incidence of ALI than non-diabetic patients, and indicate diabetic patients who do develop ALI are less likely to die than non-diabetic patients.

"People with type II diabetes develop an acquired resistance to leptin signaling -- the level of hormone is high but it does not function," Dr. Mutlu said.

In this study, diabetic and non-diabetic, wild-type mice were given bleomycin, a chemotherapy agent, to induce acute lung injury and scarring (fibrosis). Fluid and tissue samples from the lungs were obtained from both strains of mice and evaluated for lung fibrosis and levels of leptin and transforming growth factor-beta (TGF-β), a major regulator of lung fibrosis.

To determine the relationship between leptin levels and the development of ARDS in humans, lung fluid samples from ARDS patients and mechanically ventilated patients without lung disease were also taken and evaluated for levels of leptin and TGF-β.

The researchers found that while non-diaetic mice exhibited severe lung fibrosis, diabetic mice showed no signs of lung fibrosis after bleomycin treatment. Non-diabetic mice also had a sixfold increase in lung scarring compared with diabetic mice. Similarly, when evaluating the human lung fluid samples they found levels of leptin were six times higher in patients with ARDS compared to the patients without lung disease.

"We found that obese, type II diabetic mice which exhibit resistance to leptin due to lack a functional leptin receptor had much less scarring in the lung after injury," Dr. Mutlu said. "We also found evidence that leptin augments the signaling through transforming growth factor, a major regulator of lung fibrosis.

"In non-obese patients with ARDS, the levels of leptin were high and correlated with poor clinical outcomes, as indicated by death and length of stay in the intensive care unit," he added.

Dr. Mutlu said based on the results of this study therapies might be developed to prevent or lessen the severity of ARDS and ALI by increasing leptin resistance.

"Leptin is an attractive potential therapeutic target as most of its normal effects are mediated in the brain and it is relatively easy to develop drugs that are not delivered to the brain," Dr. Mutlu said. "The results of our study and those of other groups studying the effects of leptin signaling on the development of injury and fibrosis in other organs highlight the need for further prospective studies examining the influence of leptin in the outcome of patients suffering from ARDS."


Story Source:

The above story is based on materials provided by American Thoracic Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Manu Jain, GR Scott Budinger, Amy Lo, Daniela Urich, Stephanie E Rivera, Asish K Ghosh, Angel Gonzalez, Sergio E Chiarella, Katie Marks, Helen K Donnelly, Saul Soberanes, John Varga, Kathryn A Radigan, Navdeep S Chandel, Gφkhan M Mutlu. Leptin Promotes Fibroproliferative ARDS by Inhibiting Peroxisome Proliferator-activated Receptor-γ. American Journal of Respiratory and Critical Care Medicine, 2011; DOI: 10.1164/rccm.201009-1409OC

Cite This Page:

American Thoracic Society. "Leptin resistance may prevent severe lung disease in patients with diabetes." ScienceDaily. ScienceDaily, 12 February 2011. <www.sciencedaily.com/releases/2011/02/110211124611.htm>.
American Thoracic Society. (2011, February 12). Leptin resistance may prevent severe lung disease in patients with diabetes. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2011/02/110211124611.htm
American Thoracic Society. "Leptin resistance may prevent severe lung disease in patients with diabetes." ScienceDaily. www.sciencedaily.com/releases/2011/02/110211124611.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) — The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) — A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) — A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) — A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins